Trial Results, New Facilities, Approved Labels, Spinoffs, and M&As Support Long-Term Growth Strategies - Research Report on Pfizer, Johnson & Johnson, Merck, Zoetis, and AstraZeneca PR Newswire NEW YORK, July 4, 2013 NEW YORK, July 4, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Wall Street Reports announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Zoetis Inc. (NYSE: ZTS), and AstraZeneca PLC (NYSE: AZN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Pfizer Inc. Research Report On June 30, 2013, Pfizer Inc. (Pfizer) and Bristol-Myers Squibb Company announced the results of the six-month Phase III AMPLIFY trial of 5,395 patients with acute venous thromboembolism (VTE), which includes symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE). Pfizer reported that the single-agent Eliquis achieved the primary efficacy endpoint of non-inferiority to current standard of care (initial parenteral enoxaparin treatment overlapped with warfarin therapy) in the reduction of the composite endpoint of recurrent symptomatic VTE or VTE-related death. "The study results showed that apixaban, as a single-agent, has comparable efficacy with significantly fewer major bleeding events with respect to the standard of care. These results complement the previously published results for the AMPLIFY-EXT study," said Dr. Giancarlo Agnelli, Professor of Internal Medicine, University of Perugia, Italy; Director of the Department of Internal and Cardiovascular Medicine and Stroke-Unit, University Hospital, Perugia, Italy; and Lead Investigator of the study. "Together these studies represent exciting data in the field of VTE treatment and indicate that apixaban may offer an important potential alternative in both acute and extended anticoagulation therapy for VTE patients." The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/db02_PFE] -- Johnson & Johnson Research Report On June 27, 2013, Johnson & Johnson announced the opening of its Johnson & Johnson Innovation Center in Boston. According to the Company, the Boston Center is the third out of four regional hubs being established in the world's leading life science hotspots. Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals at Johnson & Johnson, commented, "The East Coast significance as a hotbed for life sciences innovation grounded in collaboration is indisputable and continues to grow. With the establishment of our Boston Innovation Center, we look forward to further fostering collaboration with some of the world's leading scientists, renowned academic centers, and influential entrepreneurs to enable future innovations that will advance human health." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/0ba3_JNJ] -- Merck & Co. Inc. Research Report On July 1, 2013, Merck & Co. Inc. (Merck) announced that the new labeling for ISENTRESS (raltegravir) film-coated tablets has been approved by the US Food and Drug Administration (FDA). Merck stated that ISENTRESS is an integrase inhibitor for the treatment of HIV-1 infection in adult patients as part of combination HIV therapy. Jürgen Rockstroh, M.D., University of Bonn, Bonn-Venusberg, Germany, stated, "As the care of HIV evolves, ISENTRESS continues to be an important treatment option for adult patients with HIV-1." Daria Hazuda, Ph.D., Vice President of Early Development and Discovery Sciences Research for Infectious Diseases at Merck, commented, "Merck has been at the forefront of HIV research for close to 30 years. The discovery of ISENTRESS and its clinical development program are a testament to Merck's long-term commitment to the research and development of medicines for HIV." The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/400f_MRK] -- Zoetis Inc. Research Report On June 24, 2013, Zoetis Inc. (Zoetis) announced that it has successfully completed its spinoff from Pfizer. Juan Ramón Alaix, CEO of Zoetis, said, "We are setting off on the next stage in our Company's life - pursuing our own initiatives and strategies as a fully independent company." He further added, "I am very proud of all the Zoetis colleagues who have prepared us for this day, while continuing to support our customers with the products, innovations and reliable supply they expect from us. We will continue serving our customers in ways that make a meaningful difference to their businesses and strengthen our position as the world leader in animal health." Zoetis reported that in accordance with the terms of the exchange offer that commenced on May 22, 2013, Pfizer has accepted shares of Pfizer stock in exchange for all of its approximately 401 million shares of Zoetis common stock. The Full Research Report on Zoetis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/7e28_ZTS] -- AstraZeneca PLC Research Report On June 28, 2013, AstraZeneca PLC (AstraZeneca) announced that it has completed the acquisition of Pearl Therapeutics and now owns 100% shares of the company. AstraZeneca stated that this acquisition provides the Company access to a potential new treatment for chronic obstructive pulmonary disease (COPD), currently in late-stage development, and inhaler and formulation technology that provides a platform for future combination products. The Full Research Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/02c7_AZN] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Trial Results, New Facilities, Approved Labels, Spinoffs, and M&As Support Long-Term Growth Strategies - Research Report on
Press spacebar to pause and continue. Press esc to stop.